



[www.probiomics.com.au](http://www.probiomics.com.au)

The Australian Stock Exchange Limited,  
Companies Announcements Office  
SYDNEY  
Via: asxonline  
16<sup>th</sup> November 2005

## Probiomics wins prestigious AJP award.

Probiomics Limited has won the 2005 AJP award for the "Best Complementary Medicines Health Product" for **proTract<sup>®</sup> IBS** – which is sold "for the relief of symptoms of medically diagnosed Irritable Bowel Syndrome".

The AJP Awards are hosted every year by the Australian Journal of Pharmacy and are highly regarded by the pharmaceutical industry in Australia. The awards were published in the November edition of the AJP.

"The awards stimulate significant competition among pharmaceutical companies for the industry recognition and kudos generated by being an AJP Award winner" said AJP publisher, David Weston.

Mr. Weston said that "in awarding Protract<sup>®</sup> IBS, the judges acknowledged that Probiomics' clinical trials have supported the inclusion of the ProTract<sup>®</sup> range of probiotics into the therapeutic environment. In addition, Probiomics has actively supported pharmacists and pharmacy staff with extensive information to encourage them to fully understand the product".

Probiomics CEO Mr. Kim Slatyer said he was delighted to have such acknowledgement from the industry. "We have been receiving congratulatory emails from some of the world's largest pharmaceutical companies".

Irritable bowel syndrome (IBS) is the most commonly encountered gastrointestinal disorder, characterized by abdominal pain, abdominal distention, and changes in bowel habits such as painful diarrhoea or constipation.

Datamonitor in 2002 estimated that the global prevalence of IBS is around 100 million sufferers the market for which will be worth in excess of \$26bn by 2010.

The company continues to advance negotiations with several large pharmaceutical companies for the marketing and distribution of the proTract<sup>®</sup> brand."

**Kim Slatyer**  
CEO

**Probiomics Limited**  
(formally VRI BioMedical Limited)

Probiomics Limited  
ACN 084 464 193 ABN 97 084 464 193  
Suite G09, 1 Central Avenue, Australian Technology Park, Eveleigh, Sydney NSW 1430, Australia  
Phone: +61 2 9209 4268 Fax: +61 2 9209 4256